Advanced Enzyme Technologies Limited has informed the Exchange regarding Allotment of 49350 Shares.
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies Limited held its Board Meeting on May 09, 2026, approving the Annual Financial Results for FY 2025-26. The company reported consolidated revenue from operations of ₹7,457.57 million, up 17.1% from ₹6,369.10 million in the previous year. Profit after tax grew significantly by 29.6% to ₹1,736.08 million from ₹1,339.74 million. The Board recommended a final dividend of ₹1.35 per equity share (67.5% on face value of ₹2), while deferring an interim dividend to preserve capital for strategic opportunities. The meeting also approved the allotment of 49,350 equity shares under the Employee Stock Option Scheme 2022, increasing paid-up capital to ₹22,39,52,300. Statutory auditors MSKA & Associates LLP issued an unmodified (clean) opinion on the financial results.
Strong financial performance with 29.6% PAT growth and clean audit opinion is positive for shareholders. The company remains financially healthy with positive operating cash flows of ₹1,567.76 million, though the deferred interim dividend may slightly disappoint investors expecting immediate returns.